Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine A Dose Reduction in Combination With Mycophenolate Mofetil in Renal Transplantation
NCT00213590Phase 3Completed
- Sponsor
- Rouen University Hospital
- Start
- Apr 2000
- Primary completion
- Nov 2006
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclosporine in kidney failure (ESRD) (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Proportion of patients with treatment failure (composite of graft loss, acute rejection, cyclosporine toxicity, or >15% increase in mean serum creatinine) at 24 months. Started Apr 2000; status: completed.
02
Drugs
cyclosporine
03
Conditions
kidney failure (ESRD)
Beyond the preview
Go deeper on NCT00213590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00213590.